Amy Conrad

Investor Relations Contact at TYRA BIOSCIENCES, INC.

Health Technology

Profile

Ms. Amy Conrad is a Founder & Chief Executive Officer at Juniper Point, Inc. and a Head-Investor Relations at Tyra Biosciences, Inc. Ms. Conrad was previously employed as a Head-Investor Relations by Anadys Pharmaceuticals, Inc., a Head-Investor Relations by Bionano Genomics, Inc., and an Investor Relations & Media Contact by Regulus Therapeutics, Inc.

Amy Conrad active positions

Companies	Position	Start
TYRA BIOSCIENCES, INC.	Investor Relations Contact	-
Juniper Point, Inc.	Chief Executive Officer	-

All active positions of Amy Conrad

Former positions of Amy Conrad

Companies	Position	End
REGULUS THERAPEUTICS INC.	Investor Relations Contact	31/12/2015
BIONANO GENOMICS, INC.	Investor Relations Contact	-
Anadys Pharmaceuticals, Inc. Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.	Investor Relations Contact	-

See the detail of Amy Conrad's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Amy Conrad's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
BIONANO GENOMICS, INC.	Health Technology
REGULUS THERAPEUTICS INC.	Health Technology
TYRA BIOSCIENCES, INC.	Health Technology

Private companies	2
Anadys Pharmaceuticals, Inc. Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.	Health Technology
Juniper Point, Inc.